Jakob Juul Rasmussen: Zero cost technology - transforming how smaller companies oversee their assets
Send us Fan Mail
Sam and Ivanna speak to Jakob Juul Rasmussen about the stubborn prevalence of paper in clinical trials, especially in small pharmaceutical and biotech companies. Paying money up front, covering the implementation and license costs and building up internal IT functions can be prohibitive for small pharmaceutical and biotech companies. This leads many companies to outsource their entire IT landscape to CROs. As a result, control over assets becomes complicated and cumbersome, as your clinical data risks being stored in different applications with multiple data models applied…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.